Adenosine receptors as emerging therapeutic targets for diabetic kidney diseaseopen access
- Authors
- Pak, Eun Seon; Cha, Jin Joo; Cha, Dae Ryong; Kanasaki, Keizo; Ha, Hunjoo
- Issue Date
- Sep-2022
- Publisher
- 대한신장학회
- Keywords
- Adenosine; Purinergic P1 receptors; Purinergic P1 receptor agonists; Purinergic P1 receptor antagonists; Diabetic kidney disease; Fibrosis
- Citation
- Kidney Research and Clinical Practice, v.41, no.S2, pp S74 - S88
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Kidney Research and Clinical Practice
- Volume
- 41
- Number
- S2
- Start Page
- S74
- End Page
- S88
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/62439
- DOI
- 10.23876/j.krcp.22.011
- ISSN
- 2211-9132
2211-9140
- Abstract
- Diabetic kidney disease (DKD) is now a pandemic worldwide, and novel therapeutic options are urgently required. Adenosine, an ade-nosine triphosphate metabolite, plays a role in kidney homeostasis through interacting with four types of adenosine receptors (ARs): A1AR, A2AAR, A2BAR, and A3AR. Increasing evidence highlights the role of adenosine and ARs in the development and progression of DKD: 1) increased adenosine in the plasma and urine of diabetics with kidney injury, 2) increased expression of each of the ARs in di-abetic kidneys, 3) the protective effect of coffee, a commonly ingested nonselective AR antagonist, on DKD, and 4) the protective ef-fect of AR modulators in experimental DKD models. We propose AR modulators as a new therapeutic option to treat DKD. Detailed mechanistic studies on the pharmacology of AR modulators will help us to develop effective first-in-class AR modulators against DKD.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Nephrology and Hypertension > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.